Abstract

Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an alpha adrenergic receptor agonist selected from selective alpha1 adrenergic receptor agonist, selective alpha2 adrenergic receptor agonist, non-selective alpha1/alpha2 adrenergic receptor agonist, agents with alpha2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.


Claims
Download PDF
Document Preview
Document History
  • Publication: Mar 18, 2014
  • Application: Jan 6, 2012
    US US 201213345472 A
  • Priority: Jan 6, 2012
    US US 201213345472 A
  • Priority: Nov 17, 2008
    US US 27225308 A
  • Priority: Nov 16, 2007
    US US 98856407 P

Sign in to the Lens